1. Scrip

Aveo Eyes Role For Tivozanib In US Kidney Cancer Market, Against The Odds

 
• By Emily Hayes

In the Phase III TIVO-3 study, tivozanib is associated with a trend toward adverse survival and trial has missing data issues.

Human kidney on scientific background. 3d illustration

Aveo Pharmaceuticals Inc. sees a role for its lead candidate tivozanib in the crowded US kidney cancer market and is gearing up for an FDA filing, but approval looks like a long shot based on results from the Phase III TIVO-3 study in heavily pretreated disease.

Cambridge, Mass.-based Aveo is pitching tivozanib, which originally was developed by Kyowa Hakko Kirin Co. Ltd., as a differentiated tyrosine kinase inhibitor (TKI)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.